QUEENSBURY, N.Y., Mar 29, 2005 (BUSINESS WIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) today announced the release of the TOTAL ABSCESSION^™ general drainage catheter, a catheter designed to percutaneously drain abscesses and other fluid collections. The TOTAL ABSCESSION drainage catheter will be available for limited distribution in the United States immediately. AngioDynamics will showcase the catheter at the Society of Interventional Radiology 2005 Annual Meeting in New Orleans, Louisiana, March 31 - April 5, 2005.

The TOTAL ABSCESSION features a tamper-resistant locking mechanism known as the VAULT^™. This unique feature eliminates additional procedures to replace drainage catheters when the locking pigtail shape becomes unlocked during routine catheter maintenance. AngioDynamics believes that the VAULT reduces physician time and increases patient comfort.

The TOTAL ABSCESSION catheter also permits aspiration while the pigtail is in either the locked or unlocked position, allowing the physician accuracy in placement and greater versatility for draining complex situations.

Commenting for AngioDynamics, Product Manager Al Concemi said, "The development of the TOTAL ABSCESSION general drainage catheter is another example of AngioDynamics' ability to create value-added proprietary products that meet the needs of our physician customers and their patients."

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. The risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended November 27, 2004, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
Al Concemi (aconcemi@angiodynamics.com)
800-772-6446 x385
http://www.angiodynamics.com/
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
212-838-3777
Bruce Voss (bvoss@lhai.com)
310-691-7100